{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:39Z","timestamp":1740147759506,"version":"3.37.3"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11739-018-1940-9","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T14:36:38Z","timestamp":1537799798000},"page":"1139-1166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)"],"prefix":"10.1007","volume":"13","author":[{"name":"on behalf of the Italian Society of Nephrology (SIN)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-2089","authenticated-orcid":false,"given":"Roberto","family":"Minutolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Italian Association for the Study of the Liver (AISF)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Italian Society of Infectious and Tropical Disease (SIMIT)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Italian Society of Internal Medicine (SIMI)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Chirianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Fabrizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo G.","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Montinaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Persico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perticone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rendina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Linda","family":"Zignego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease","year":"2013","unstructured":"Kidney Disease (2013) Improving global outcomes (KDIGO) CKD Work Group. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1\u2013150","journal-title":"Kidney Int Suppl"},{"key":"1940_CR2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ndt\/gfu383","volume":"30","author":"L Nicola De","year":"2015","unstructured":"De Nicola L, Donfrancesco C, Minutolo R et al (2015) Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008\u201312 National Health Examination Survey. Nephrol Dial Transpl 30:806\u2013814","journal-title":"Nephrol Dial Transpl"},{"key":"1940_CR3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2369-10-24","volume":"10","author":"G Gentile","year":"2009","unstructured":"Gentile G, Postorino M, Mooring RD et al (2009) Estimated GFR reporting is not sufficient to allow detection of chronic kidney disease in an Italian regional hospital. BMC Nephrol 10:24","journal-title":"BMC Nephrol"},{"key":"1940_CR4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/j.ajkd.2008.03.002","volume":"52","author":"R Minutolo","year":"2008","unstructured":"Minutolo R, De Nicola L, Mazzaglia G et al (2008) Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross sectional study from Italy. Am J Kidney Dis 52:444\u2013453","journal-title":"Am J Kidney Dis"},{"key":"1940_CR5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/jvh.12199","volume":"21","author":"WC Li","year":"2014","unstructured":"Li WC, Lee YY, Chen IC, Wang SH, Hsiao CT, Loke SS (2014) Age and gender differences in the relationship between hepatitis C infection and all stages of chronic kidney disease. J Viral Hepat 21:706\u2013715","journal-title":"J Viral Hepat"},{"key":"1940_CR6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12072-011-9284-9","volume":"6","author":"SK Satapathy","year":"2012","unstructured":"Satapathy SK, Lingisetty CS, Williams S (2012) Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int 6:369\u2013378","journal-title":"Hepatol Int"},{"key":"1940_CR7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/jvh.12414","volume":"22","author":"X Tong","year":"2015","unstructured":"Tong X, Spradling PR (2015) Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004\u20132011. J Viral Hepat 22:906\u2013913","journal-title":"J Viral Hepat"},{"key":"1940_CR8","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3748\/wjg.v20.i10.2533","volume":"20","author":"N Rognant","year":"2014","unstructured":"Rognant N, Lemoine S (2014) Evaluation of renal function in patients with cirrhosis: where are we now? World J Gastroenterol 20:2533\u20132541","journal-title":"World J Gastroenterol"},{"key":"1940_CR9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ndt\/gfv427","volume":"31","author":"L Nicola De","year":"2016","unstructured":"De Nicola L, Zoccali C (2016) Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transpl 31:331\u2013335","journal-title":"Nephrol Dial Transpl"},{"key":"1940_CR10","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1681\/ASN.2006020156","volume":"17","author":"M Yoshino","year":"2006","unstructured":"Yoshino M, Kuhlmann MK, Kotanko P et al (2006) International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 17:3510\u20133519","journal-title":"J Am Soc Nephrol"},{"key":"1940_CR11","first-page":"e34(1)","volume":"368","author":"R Estruch","year":"2018","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J et al (2018) Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 378:e34(1)\u2013e34(14)","journal-title":"N Engl J Med"},{"key":"1940_CR12","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.2215\/CJN.01780213","volume":"8","author":"X Huang","year":"2013","unstructured":"Huang X, Jim\u00e9nez-Mole\u00f3n JJ, Lindholm B et al (2013) Mediterranean diet, kidney function, and mortality in men with CKD. Clin J Am Soc Nephrol 8:1548\u20131555","journal-title":"Clin J Am Soc Nephrol"},{"key":"1940_CR13","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154\u20132169","journal-title":"Circulation"},{"key":"1940_CR14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli M, Muntner P, Lloyd A et al (2012) Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380:807\u2013814","journal-title":"Lancet"},{"key":"1940_CR15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.ki.5000085","volume":"69","author":"L Nicola De","year":"2006","unstructured":"De Nicola L, Minutolo R, Chiodini P et al (2006) on behalf of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int 69:538\u2013545","journal-title":"Kidney Int"},{"key":"1940_CR16","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2215\/CJN.01180211","volume":"6","author":"L Nicola De","year":"2011","unstructured":"De Nicola L, Chiodini P, Zoccali C et al, for the SIN-TABLE CKD Study Group (2011) Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 6:2421\u20132428","journal-title":"Clin J Am Soc Nephrol"},{"key":"1940_CR17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ki.2012.174","volume":"82","author":"L Nicola De","year":"2012","unstructured":"De Nicola L, Minutolo R, Chiodini P et al (2012) The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. Kidney Int 82:482\u2013488","journal-title":"Kidney Int"},{"issue":"5","key":"1940_CR18","doi-asserted-by":"crossref","first-page":"e0127071","DOI":"10.1371\/journal.pone.0127071","volume":"10","author":"L Nicola De","year":"2015","unstructured":"De Nicola L, Provenzano M, Chiodini P et al (2015) Independent role of underlying kidney disease on renal prognosis of patients with chronic kidney disease under nephrology care. PLoS One 10(5):e0127071","journal-title":"PLoS One"},{"key":"1940_CR19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1523-1755.2002.00432.x","volume":"62","author":"SS Khan","year":"2002","unstructured":"Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT (2002) Health care utilization among patients with chronic kidney disease. Kidney Int 62:229\u2013236","journal-title":"Kidney Int"},{"key":"1940_CR20","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296\u20131305","journal-title":"N Engl J Med"},{"key":"1940_CR21","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.ajkd.2016.09.018","volume":"69","author":"J Ishigami","year":"2017","unstructured":"Ishigami J, Grams ME, Chang AR et al (2017) CKD and risk for hospitalization with infection: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis 69:752\u2013761","journal-title":"Am J Kidney Dis"},{"key":"1940_CR22","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2215\/CJN.04480415","volume":"10","author":"Y Xie","year":"2015","unstructured":"Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z (2015) Rate of kidney function decline and risk of hospitalizations in stage 3A CKD. Clin J Am Soc Nephrol 10:1946\u20131955","journal-title":"Clin J Am Soc Nephrol"},{"key":"1940_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1\u2013138","journal-title":"Kidney Int Suppl"},{"key":"1940_CR24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2015.02.338","volume":"66","author":"MT James","year":"2015","unstructured":"James MT, Grams ME, Woodward M et al (2015) A Meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. Am J Kidney Dis 66:602\u2013612","journal-title":"Am J Kidney Dis"},{"key":"1940_CR25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jvh.12437","volume":"23","author":"GN Nadkarni","year":"2016","unstructured":"Nadkarni GN, Patel A, Simoes PK et al (2016) Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis. J Viral Hepat 23:32\u201338","journal-title":"J Viral Hepat"},{"key":"1940_CR26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/cc5564","volume":"11","author":"JA Lopes","year":"2007","unstructured":"Lopes JA, Fernandes J, Jorge S, Neves J, Antunes F, Prata MM (2007) Acute renal failure in critically ill HIV-infected patients. Crit Care 11:404","journal-title":"Crit Care"},{"key":"1940_CR27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.qai.0000220165.79736.d3","volume":"42","author":"N Franceschini","year":"2006","unstructured":"Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJJ (2006) Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients. J Acquir Immune Defic Syndr 42:368\u2013372","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1940_CR28","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1097\/QAD.0b013e32830e0152","volume":"22","author":"C Wyatt","year":"2008","unstructured":"Wyatt C, Malvestutto C, Coca S, Klotman P, Parikh C (2008) The impact of hepatitis C virus co-infection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 22:1799\u20131807","journal-title":"AIDS"},{"key":"1940_CR29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/apc.2010.0104","volume":"25","author":"S Garg","year":"2011","unstructured":"Garg S, Hoenig M, Edwards E et al (2011) Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus co-infection. AIDS Patient Care 25:135\u2013141","journal-title":"AIDS Patient Care"},{"key":"1940_CR30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ki.2011.379","volume":"81","author":"SG Coca","year":"2012","unstructured":"Coca SG, Singanamala S, Parikh CR (2012) Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81:442\u2013448","journal-title":"Kidney Int"},{"key":"1940_CR31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ki.2011.405","volume":"81","author":"ID Bucaloiu","year":"2012","unstructured":"Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE, Perkins RM (2012) Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 81:477\u2013485","journal-title":"Kidney Int"},{"key":"1940_CR32","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.2215\/CJN.10481013","volume":"9","author":"R Minutolo","year":"2014","unstructured":"Minutolo R, Lapi F, Chiodini P et al (2014) Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective study. Clin J Am Soc Nephrol 9:1586\u20131593","journal-title":"Clin J Am Soc Nephrol"},{"key":"1940_CR33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.amjmed.2007.04.024","volume":"120","author":"MR Chan","year":"2007","unstructured":"Chan MR, Dall AT, Fletcher KE et al (2007) Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med 120:1063\u20131070","journal-title":"Am J Med"},{"key":"1940_CR34","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1053\/ajkd.2001.28619","volume":"38","author":"K McLaughlin","year":"2001","unstructured":"McLaughlin K, Manns B, Culleton B et al (2001) An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis 38:1122\u20131128","journal-title":"Am J Kidney Dis"},{"key":"1940_CR35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.autrev.2017.03.004","volume":"16","author":"AL Zignego","year":"2017","unstructured":"Zignego AL, Ramos-Casals M, Ferri C et al (2017) ISG-EHCV. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev 16:523\u2013541","journal-title":"Autoimmun Rev"},{"key":"1940_CR36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000168641","volume":"13","author":"A Pasquariello","year":"1993","unstructured":"Pasquariello A, Ferri C, Moriconi L, La Civita L, Longombardo G, Lombardini F, Greco F, Zignego AL (1993) Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus. Am J Nephrol 13:300\u2013304","journal-title":"Am J Nephrol"},{"key":"1940_CR37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-144-10-200605160-00007","volume":"144","author":"BM McGuire","year":"2006","unstructured":"McGuire BM, Julian BA, Bynon JS et al (2006) Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 144:735\u2013741","journal-title":"Ann Intern Med"},{"key":"1940_CR38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2012.08.040","volume":"61","author":"F Fabrizi","year":"2013","unstructured":"Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P (2013) Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis 61:623\u2013637","journal-title":"Am J Kidney Dis"},{"key":"1940_CR39","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/ndt\/gfm205","volume":"22","author":"RS Barsoum","year":"2007","unstructured":"Barsoum RS (2007) Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transpl 22:1840\u20131848","journal-title":"Nephrol Dial Transpl"},{"key":"1940_CR40","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","volume":"42","author":"P Cacoub","year":"1999","unstructured":"Cacoub P, Poynard T, Ghillani P et al (1999) Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C Arthritis Rheum 42:2204\u20132212","journal-title":"Multidepartment Virus C Arthritis Rheum"},{"issue":"10","key":"1940_CR41","doi-asserted-by":"crossref","first-page":"e1004424","DOI":"10.1371\/journal.ppat.1004424","volume":"10","author":"TN Bukong","year":"2014","unstructured":"Bukong TN, Momen-Heravi F, Kodys K, Bala S, Szabo G (2014) Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog 10(10):e1004424","journal-title":"PLoS Pathog"},{"key":"1940_CR42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2893.2000.00194.x","volume":"7","author":"E Rodr\u00edguez-I\u00f1igo","year":"2000","unstructured":"Rodr\u00edguez-I\u00f1igo E, Casqueiro M, Bartolom\u00e9 J et al (2000) Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases. J Viral Hepat 7:23\u201329","journal-title":"J Viral Hepat"},{"key":"1940_CR43","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.510250529","volume":"25","author":"D Sansonno","year":"1997","unstructured":"Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F (1997) Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 25:1237\u20131244","journal-title":"Hepatology"},{"key":"1940_CR44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/1744666X.2015.997214","volume":"11","author":"AL Zignego","year":"2015","unstructured":"Zignego AL, Gragnani L, Piluso A et al (2015) Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol 11:15\u201331","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 4","key":"1940_CR45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ndt\/11.supp4.25","volume":"11","author":"A Fornasieri","year":"1996","unstructured":"Fornasieri A, D\u2019Amico G (1996) Type II mixed cryoglobulinaemia, hepatitis C virus infection, and glomerulonephritis. Nephrol Dial Transpl 11(Suppl 4):25\u201330","journal-title":"Nephrol Dial Transpl"},{"key":"1940_CR46","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1681\/ASN.2007040395","volume":"19","author":"MC Banas","year":"2008","unstructured":"Banas MC, Banas B, Hudkins KL et al (2008) TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 19:704\u2013713","journal-title":"J Am Soc Nephrol"},{"key":"1940_CR47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2353\/ajpath.2006.050491","volume":"168","author":"M W\u00f6rnle","year":"2006","unstructured":"W\u00f6rnle M, Schmid H, Banas B et al (2006) Novel role of toll-like receptor 3in hepatitis C-associated glomerulonephritis. Am J Pathol 168:370\u2013385","journal-title":"Am J Pathol"},{"key":"1940_CR48","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/hep.29192","volume":"66","author":"TS Lai","year":"2017","unstructured":"Lai TS, Lee MH, Yang HI et al (2017) REVEAL-HCV Study Group Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology 66:784\u2013793","journal-title":"Hepatology"},{"key":"1940_CR49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0272-6386(03)00024-6","volume":"41","author":"K Kasuno","year":"2003","unstructured":"Kasuno K, Ono T, Matsumori A et al (2003) Hepatitis C virus-associated tubulointerstitial injury. Am J Kidney Dis 41:767\u2013775","journal-title":"Am J Kidney Dis"},{"key":"1940_CR50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0923-2516(99)89011-6","volume":"149","author":"C Bosman","year":"1998","unstructured":"Bosman C, Valli MB, Bertolini L et al (1998) Detection of virus-like particles in liver biopsies from HCV-infected patients. Res Virol 149:311\u2013314","journal-title":"Res Virol"},{"key":"1940_CR51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2005.01.013","volume":"334","author":"A Sabry","year":"2005","unstructured":"Sabry A, E-Agroudy A, Sheashaa H et al (2005) HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis. Virology 334:10\u201316","journal-title":"Virology"},{"key":"1940_CR52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","volume":"328","author":"RJ Johnson","year":"1993","unstructured":"Johnson RJ, Gretch DR, Yamabe H et al (1993) Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328:465\u2013470","journal-title":"N Engl J Med"},{"key":"1940_CR53","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.V62220","volume":"6","author":"H Yamabe","year":"1995","unstructured":"Yamabe H, Johnson RJ, Gretch DR et al (1995) Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 6:220\u2013223","journal-title":"J Am Soc Nephrol"},{"key":"1940_CR54","first-page":"813","volume":"21","author":"F Fabrizi","year":"2008","unstructured":"Fabrizi F, Lunghi G, Messa P, Martin P (2008) Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 21:813\u2013825","journal-title":"J Nephrol"},{"key":"1940_CR55","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0272-6386(03)00828-X","volume":"42","author":"CM Meyers","year":"2003","unstructured":"Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH (2003) Hepatitis C and renal disease: an update. Am J Kidney Dis 42:631\u2013657","journal-title":"Am J Kidney Dis"},{"key":"1940_CR56","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00005792-200209000-00005","volume":"81","author":"S Beddhu","year":"2002","unstructured":"Beddhu S, Bastacky S, Johnson JP (2002) The clinical and morphologic spectrum of renal cryoglobulinemia. Med (Baltim) 81:398\u2013409","journal-title":"Med (Baltim)"},{"key":"1940_CR57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.autrev.2016.09.006","volume":"15","author":"C Ferri","year":"2016","unstructured":"Ferri C, Ramos-Casals M, Zignego AL et al (2016) International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev 15:1145\u20131160","journal-title":"Autoimmun Rev"},{"key":"1940_CR58","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2169\/internalmedicine.37.836","volume":"37","author":"Y Arase","year":"1998","unstructured":"Arase Y, Ikeda K, Murashima N et al (1998) Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med 37:836\u2013840","journal-title":"Intern Med"},{"key":"1940_CR59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000168874","volume":"15","author":"IH Altraif","year":"1995","unstructured":"Altraif IH, Abdulla AS, al Sebayel MI, Said RA, al Suhaibani MO, Jones AA (1995) Hepatitis C associated glomerulonephritis. Am J Nephrol 15:407\u2013410","journal-title":"Am J Nephrol"},{"key":"1940_CR60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000186573","volume":"59","author":"C Rollino","year":"1991","unstructured":"Rollino C, Roccatello D, Giachino O, Basolo B, Piccoli G (1991) Hepatitis C virus infection and membranous glomerulonephritis. Nephron 59:319\u2013320","journal-title":"Nephron"},{"key":"1940_CR61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5414\/CN107337","volume":"80","author":"CJ Sperati","year":"2013","unstructured":"Sperati CJ (2013) Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha- 2a and ribavirin. Clin Nephrol 80:231\u2013234","journal-title":"Clin Nephrol"},{"key":"1940_CR62","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3109\/0886022X.2013.815568","volume":"35","author":"HH Shah","year":"2013","unstructured":"Shah HH, Patel C (2013) Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis. Ren Fail 35:1182\u20131185","journal-title":"Ren Fail"},{"key":"1940_CR63","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2169\/internalmedicine.49.4365","volume":"49","author":"F Ji","year":"2010","unstructured":"Ji F, Li Z, Ge H, Deng H (2010) Successful interferon-\u03b1 treatment in a patient with IgA nephropathy associated with hepatitis C virus infection. Intern Med 49:2531\u20132532","journal-title":"Intern Med"},{"key":"1940_CR64","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000188494","volume":"69","author":"A Gonzalo","year":"1995","unstructured":"Gonzalo A, Navarro J, B\u00e1rcena R, Quereda C, Ortu\u00f1o J (1995) IgA nephropathy associated with hepatitis C virus infection. Nephron 69:354","journal-title":"Nephron"},{"key":"1940_CR65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/0971-4065.109443","volume":"23","author":"AK Dey","year":"2013","unstructured":"Dey AK, Bhattacharya A, Majumdar A (2013) Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol 23:143\u2013145","journal-title":"Indian J Nephrol"},{"key":"1940_CR66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0272-6386(12)70138-5","volume":"22","author":"A Fogo","year":"1993","unstructured":"Fogo A, Qureshi N, Horn RG (1993) Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 22:367\u2013377","journal-title":"Am J Kidney Dis"},{"key":"1940_CR67","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0272-6386(97)90020-2","volume":"29","author":"E Coroneos","year":"1997","unstructured":"Coroneos E, Truong L, Olivero J (1997) Fibrillary glomerulonephritis associated with hepatitis C viral infection. Am J Kidney Dis 29:132\u2013135","journal-title":"Am J Kidney Dis"},{"key":"1940_CR68","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5414\/CNP60364","volume":"60","author":"G Guerra","year":"2003","unstructured":"Guerra G, Narayan G, Rennke HG, Jaber BL (2003) Crescentic fibrillary glomerulonephritis associated with hepatitis C viral infection. Clin Nephrol 60:364\u2013368","journal-title":"Clin Nephrol"},{"key":"1940_CR69","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1046\/j.1523-1755.1998.t01-1-00094.x","volume":"53","author":"HR Brady","year":"1998","unstructured":"Brady HR (1998) Fibrillary glomerulopathy. Kidney Int 53:1421\u20131429","journal-title":"Kidney Int"},{"key":"1940_CR70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11894-001-0045-0","volume":"3","author":"M Philipneri","year":"2001","unstructured":"Philipneri M, Bastani B (2001) Kidney disease in patients with chronic hepatitis C. Curr Gastroenterol Rep 3:79\u201383","journal-title":"Curr Gastroenterol Rep"},{"key":"1940_CR71","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2008.06.003","volume":"49","author":"P Martin","year":"2008","unstructured":"Martin P, Fabrizi F (2008) Hepatitis C virus and kidney disease. J Hepatol 49:613\u2013624","journal-title":"J Hepatol"},{"key":"1940_CR72","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00007890-199803150-00024","volume":"65","author":"D Hestin","year":"1998","unstructured":"Hestin D, Guillemin F, Castin N, Le Faou A, Champigneulles J, Kessler M (1998) Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation 65:741\u2013744","journal-title":"Transplantation"},{"key":"1940_CR73","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0272-6386(96)90260-7","volume":"28","author":"FG Cosio","year":"1996","unstructured":"Cosio FG, Roche Z, Agarwal A, Falkenhain ME, Sedmak DD, Ferguson RM (1996) Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 28:752\u2013758","journal-title":"Am J Kidney Dis"},{"key":"1940_CR74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","volume":"29","author":"P Mathurin","year":"1999","unstructured":"Mathurin P, Mouquet C, Poynard T et al (1999) Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29:257\u2013263","journal-title":"Hepatology"},{"key":"1940_CR75","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/00007890-199506270-00006","volume":"59","author":"D Roth","year":"1995","unstructured":"Roth D, Cirocco R, Zucker K et al (1995) De novo membranoproliferative glomerulonephritis in hepatitis C virus-infectedrenal allograft recipients. Transplantation 59:1676\u20131682","journal-title":"Transplantation"},{"key":"1940_CR76","doi-asserted-by":"crossref","first-page":"c133","DOI":"10.1159\/000085442","volume":"100","author":"I Mahmoud","year":"2005","unstructured":"Mahmoud I, Sobh M, El-Habashi A et al (2005) Interferon therapy in haemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 100:c133\u2013c139","journal-title":"Nephron Clin Pract"},{"key":"1940_CR77","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/00007890-199706150-00017","volume":"63","author":"JM Morales","year":"1997","unstructured":"Morales JM, Pascual-Capdevila J, Campistol JM et al (1997) Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 63:1634\u20131639","journal-title":"Transplantation"},{"key":"1940_CR78","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2004.12.014","volume":"45","author":"S Bergman","year":"2005","unstructured":"Bergman S, Accortt N, Turner A, Glaze J (2005) Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 45:684\u2013689","journal-title":"Am J Kidney Dis"},{"key":"1940_CR79","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10620-015-3918-z","volume":"61","author":"S Rogal","year":"2016","unstructured":"Rogal S, Yan P, Rimland D et al (2016) Electronically retrieved cohort of HCV infected veterans study group. Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES. Dig Dis Sci 61:930\u2013936","journal-title":"Dig Dis Sci"},{"key":"1940_CR80","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5604\/01.3001.0011.7382","volume":"17","author":"F Fabrizi","year":"2018","unstructured":"Fabrizi F, Donato FM, Messa P (2018) Association between hepatitis C virus and chronic kidney disease: a systematic review and meta-analysis. Ann Hepatol 17:364\u2013391","journal-title":"Ann Hepatol"},{"key":"1940_CR81","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/ajkd.2001.28590","volume":"38","author":"F Fabrizi","year":"2001","unstructured":"Fabrizi F, Lunghi G, Finazzi S et al (2001) Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 38:1009\u20131015","journal-title":"Am J Kidney Dis"},{"key":"1940_CR82","first-page":"151","volume":"54","author":"M Espinosa","year":"2000","unstructured":"Espinosa M, Martin-Malo A, Alvarez de Lara M, Soriano S, Aljama P (2000) High ALT levels predict viremia in anti-HCV positive HD patients if a modified normal range of ALT is applied. Clin Nephrol 54:151\u2013156","journal-title":"Clin Nephrol"},{"key":"1940_CR83","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4254\/wjh.v7.i10.1377","volume":"7","author":"H Li","year":"2015","unstructured":"Li H, Lo S (2015) Hepatitis C virus: virology, diagnosis and treatment. World J Hepatol 7:1377\u20131389","journal-title":"World J Hepatol"},{"key":"1940_CR84","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2893.2001.00280.x","volume":"8","author":"C Colin","year":"2001","unstructured":"Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C (2001) Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 8:87\u201395","journal-title":"J Viral Hepat"},{"key":"1940_CR85","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1128\/JCM.36.6.1711-1715.1998","volume":"36","author":"P Schneeberger","year":"1998","unstructured":"Schneeberger P, Keur I, van der Vliet W et al (1998) Hepatitis C virus infection in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 36:1711\u20131715","journal-title":"J Clin Microbiol"},{"key":"1940_CR86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1423-0410.1995.tb02538.x","volume":"68","author":"J Barrera","year":"1995","unstructured":"Barrera J, Francis B, Ercilla G et al (1995) Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 68:15\u201318","journal-title":"Vox Sang"},{"key":"1940_CR87","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1542-4758.2011.00662.x","volume":"16","author":"A El-Sherif","year":"2012","unstructured":"El-Sherif A, Elbahrawy A, Aboelfotoh A et al (2012) High false-negative rate of anti-HCV among Egyptian patients on regular haemodialysis. Hemodial Int 16:420\u2013427","journal-title":"Hemodial Int"},{"issue":"Suppl 109","key":"1940_CR88","first-page":"S1","volume":"73","author":"Kidney Disease","year":"2008","unstructured":"Kidney Disease (2008) Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int 73(Suppl 109):S1\u2013S99","journal-title":"Kidney Int"},{"key":"1940_CR89","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69:461\u2013511","journal-title":"J Hepatol"},{"key":"1940_CR90","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1572-0241.2000.01773.x","volume":"95","author":"N Furusyo","year":"2000","unstructured":"Furusyo N, Hayashi J, Ariyama I et al (2000) Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in haemodialysis patients with chronic HCV infection. Am J Gastroenterol 95:490\u2013496","journal-title":"Am J Gastroenterol"},{"key":"1940_CR91","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333\u20131342","journal-title":"Hepatology"},{"key":"1940_CR92","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2337\/diacare.28.9.2187","volume":"28","author":"E Crook","year":"2005","unstructured":"Crook E, Penumalee S, Gavini B, Filippova K (2005) Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 28:2187\u20132191","journal-title":"Diabetes Care"},{"key":"1940_CR93","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000319456","volume":"32","author":"L Noureddine","year":"2010","unstructured":"Noureddine L, Usman S, Yu Z, Moorthi R, Moe S (2010) Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol 32:311\u2013316","journal-title":"Am J Nephrol"},{"key":"1940_CR94","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jmv.24353","volume":"88","author":"F Fabrizi","year":"2016","unstructured":"Fabrizi F, Dixit V, Martin P, Messa P (2016) Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. J Med Virol 88:487\u2013497","journal-title":"J Med Virol"},{"key":"1940_CR95","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.kint.2017.03.021","volume":"92","author":"T Lai","year":"2017","unstructured":"Lai T, Lee M, Yang H et al (2017) High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. Kidney Int 92:703\u2013709","journal-title":"Kidney Int"},{"key":"1940_CR96","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.23756","volume":"20","author":"M Bl\u00e8","year":"2014","unstructured":"Bl\u00e8 M, Aguilera V, Rubin A et al (2014) Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl 20:25\u201334","journal-title":"Liver Transpl"},{"key":"1940_CR97","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1872-034X.2011.00845.x","volume":"41","author":"Y Arase","year":"2011","unstructured":"Arase Y, Suzuki F, Kawamura Y et al (2011) Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res 41:946\u2013954","journal-title":"Hepatol Res"},{"key":"1940_CR98","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","volume":"59","author":"Y Hsu","year":"2014","unstructured":"Hsu Y, Lin J, Ho H et al (2014) Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59:1293\u20131302","journal-title":"Hepatology"},{"key":"1940_CR99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","volume":"64","author":"Y Hsu","year":"2015","unstructured":"Hsu Y, Ho H, Huang Y et al (2015) Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64:495\u2013503","journal-title":"Gut"},{"key":"1940_CR100","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.1097\/MD.0000000000001334","volume":"94","author":"Y Chen","year":"2015","unstructured":"Chen Y, Hwang S, Li C, Wu C, Lin L (2015) A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease. Med (Baltim) 94:e1334","journal-title":"Med (Baltim)"},{"key":"1940_CR101","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.gastrohep.2012.01.015","volume":"35","author":"SR Aoufi","year":"2012","unstructured":"Aoufi SR, Garc\u00eda RA, Ten\u00edas Burillo JM et al (2012) Microalbuminuria and renal insufficiency in chronic hepatitis C virus infection. Gastroenterol Hepatol 35:309\u2013316","journal-title":"Gastroenterol Hepatol"},{"key":"1940_CR102","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s10096-016-2692-y","volume":"35","author":"S Leone","year":"2016","unstructured":"Leone S, Prosperi M, Costarelli S et al (2016) Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV\/HCV-coinfected patients who achieved sustained virological response. Eur J Clin Microbiol Infect Dis 35:1511\u20131520","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1940_CR103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcv.2009.10.005","volume":"47","author":"M Boddi","year":"2010","unstructured":"Boddi M, Abbate R, Chellini B et al (2010) Hepatitis C virus RNA localization in human carotid plaque. J Clin Virol 47:72\u201375","journal-title":"J Clin Virol"},{"key":"1940_CR104","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3748\/wjg.v20.i13.3410","volume":"20","author":"L Adinolfi","year":"2014","unstructured":"Adinolfi L, Zampino R, Restivo L et al (2014) Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 20:3410\u20133417","journal-title":"World J Gastroenterol"},{"key":"1940_CR105","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","volume":"61","author":"M Molnar","year":"2015","unstructured":"Molnar M, Alhourani H, Wall B et al (2015) Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61:1495\u20131502","journal-title":"Hepatology"},{"key":"1940_CR106","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000093107","volume":"34","author":"M Sabovic","year":"2005","unstructured":"Sabovic M, Salobir B, Preloznik Zupan I et al (2005) The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis. Pathophysiol Haemost Thromb 34:274\u2013278","journal-title":"Pathophysiol Haemost Thromb"},{"key":"1940_CR107","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2010.12.019","volume":"57","author":"C Manno","year":"2011","unstructured":"Manno C, Bonifati C, Torres D, Campobasso N, Schena F (2011) Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis 57:850\u2013855","journal-title":"Am J Kidney Dis"},{"key":"1940_CR108","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.21681","volume":"46","author":"LL Schiavon","year":"2007","unstructured":"Schiavon LL, Schiavon JL, Filho RJ et al (2007) Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 46:307\u2013314","journal-title":"Hepatology"},{"key":"1940_CR109","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.04320510","volume":"6","author":"CH Liu","year":"2011","unstructured":"Liu CH, Liang CC, Huang KW et al (2011) Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol 6:1057\u20131065","journal-title":"Clin J Am Soc Nephrol"},{"key":"1940_CR110","doi-asserted-by":"crossref","first-page":"c289","DOI":"10.1159\/000320751","volume":"117","author":"M Canbakan","year":"2011","unstructured":"Canbakan M, Senturk H, Canbakan B et al (2011) Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C. Nephron Clin Pract 117:c289\u2013295","journal-title":"Nephron Clin Pract"},{"issue":"Suppl 1","key":"1940_CR111","first-page":"34","volume":"12","author":"G D\u2019Amico","year":"2017","unstructured":"D\u2019Amico G, Morabito A, D\u2019Amico M et al (2017) New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int 12(Suppl 1):34\u201343","journal-title":"Hepatol Int"},{"key":"1940_CR112","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1471-2334-12-265","volume":"12","author":"W Alashek","year":"2012","unstructured":"Alashek W, McIntyre C, Taal M (2012) Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis 12:265","journal-title":"BMC Infect Dis"},{"key":"1940_CR113","first-page":"188","volume":"33","author":"R Garcia-Agudo","year":"2013","unstructured":"Garcia-Agudo R, Aoufi-Rabih S, Barril-Cuadrado G (2013) Grupo de Virus en Dialisis de la Sociedad Espanola de Nefrologia. SHECTS multi-centre Spanish Study: liver situation of patients with chronic hepatitis from HCV on renal replacement therapy with haemodialysis. Nefrologia 33:188\u2013195","journal-title":"Nefrologia"},{"key":"1940_CR114","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","volume":"38","author":"D Goodkin","year":"2013","unstructured":"Goodkin D, Bieber B, Gillespie B, Robinson B, Jadoul M (2013) Hepatitis C infection is very rarely treated among haemodialysis patients. Am J Nephrol 38:405\u2013412","journal-title":"Am J Nephrol"},{"key":"1940_CR115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.11604\/pamj.2014.19.305.5639","volume":"19","author":"I Ummate","year":"2014","unstructured":"Ummate I, Denue B, Kida I, Ohioma O, Baba D, Goni W (2014) Risk factors for hepatitis C virus seropositivity among haemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria. Pan Afr Med J 19:305","journal-title":"Pan Afr Med J"},{"key":"1940_CR116","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4103\/1319-2442.132236","volume":"25","author":"Z Lioussfi","year":"2014","unstructured":"Lioussfi Z, Errami Z, Radoui A et al (2014) Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl 25:672\u2013679","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"1940_CR117","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12985-015-0238-z","volume":"12","author":"B Vidales-Braz","year":"2015","unstructured":"Vidales-Braz B, da Silva N, Lobato R et al (2015) Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in haemodialysis patients. Virol J 12:8","journal-title":"Virol J"},{"key":"1940_CR118","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12889-015-1532-9","volume":"15","author":"C Duong","year":"2015","unstructured":"Duong C, Olszyna D, McLaws M (2015) Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC Public Health 15:192","journal-title":"BMC Public Health"},{"key":"1940_CR119","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/0976-9668.175076","volume":"7","author":"R Malhotra","year":"2016","unstructured":"Malhotra R, Soin D, Grover P, Galhotra S, Khutan H, Kaur N (2016) Hepatitis B virus and hepatitis C virus co-infection in haemodialysis patients: a retrospective study from a tertiary care hospital of North India. J Nat Sci Biol Med 7:72\u201374","journal-title":"J Nat Sci Biol Med"},{"key":"1940_CR120","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5301\/ijao.5000437","volume":"38","author":"F Fabrizi","year":"2015","unstructured":"Fabrizi F, Messa P (2015) Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs 38:471\u2013480","journal-title":"Int J Artif Organs"},{"key":"1940_CR121","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-150-1-200901060-00007","volume":"150","author":"N Thompson","year":"2009","unstructured":"Thompson N, Perz J, Moorman A, Holmberg S (2009) Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998\u20132008. Ann Intern Med 150:33\u201339","journal-title":"Ann Intern Med"},{"key":"1940_CR122","unstructured":"Centers for Disease Control. Hepatitis: control measures for hepatitis B in dialysis centers. Altlanta, GA: US Department of Health, Education and Welfare; 1977. HEW publication no. (CDC) 78-8358"},{"key":"1940_CR123","first-page":"1","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","unstructured":"Centers for Disease Control and Prevention (2001) Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR Morb Mortal Wkly Rep 50:1\u201343","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1940_CR124","first-page":"875","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention (2008) Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. MMWR Morb Mortal Wkly Rep 57:875\u2013876","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1940_CR125","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.ajkd.2013.03.011","volume":"62","author":"P Patel","year":"2013","unstructured":"Patel P, Yi S, Booth S et al (2013) Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort in a quality improvement report. Am J Kidney Dis 62:322\u2013330","journal-title":"Am J Kidney Dis"},{"key":"1940_CR126","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/ndt\/gfh759","volume":"20","author":"M Arenas","year":"2005","unstructured":"Arenas M, Sanchez-Paya J et al (2005) A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transpl 20:1164\u20131171","journal-title":"Nephrol Dial Transpl"},{"key":"1940_CR127","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfh012","volume":"19","author":"M Jadoul","year":"2004","unstructured":"Jadoul M, Poignet J, Geddes C et al (2004) The changing epidemiology of hepatitis C virus infection in haemodialysis: European multicentre study. Nephrol Dial Transpl 19:904\u2013909","journal-title":"Nephrol Dial Transpl"},{"key":"1940_CR128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jhin.2016.07.021","volume":"94","author":"S Senatore","year":"2016","unstructured":"Senatore S, Galli C, Conti A et al (2016) Hepatitis C virus outbreak in a haemodialysis unit: learning from failures. J Hosp Infect 94:249\u2013252","journal-title":"J Hosp Infect"},{"key":"1940_CR129","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.15585\/mmwr.mm6450a5","volume":"64","author":"D Muleta","year":"2016","unstructured":"Muleta D, Kainer M, Moore-Moravian L et al (2016) Notes from the field: hepatitis C outbreak in a dialysis clinic\u2014Tennessee, 2014. MMWR Morb Mortal Wkly Rep 64:1386\u20131387","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1940_CR130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/ice.2015.247","volume":"37","author":"D Nguyen","year":"2016","unstructured":"Nguyen D, Gutowoski J, Ghiselli M et al (2016) A large outbreak of hepatitis C virus infections in a haemodialysis clinic. Infect Control Hosp Epidemiol 37:125\u2013133","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1940_CR131","unstructured":"Centers for Disease Control and Prevention (2017) Healthcare-associated hepatitis B and C outbreaks (\u2265 2 cases) reported to the Centers for Disease Control and Prevention (CDC) 2008\u20132016. https:\/\/www.cdc.gov\/hepatitis\/outbreaks\/healthcarehepoutbreaktable.htm . Accessed 4 Aug 2017"},{"key":"1940_CR132","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/ajt.13811","volume":"16","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention (2016) CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing haemodialysis. Am J Transpl 16:1633\u20131634","journal-title":"Am J Transpl"},{"key":"1940_CR133","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/659407","volume":"32","author":"G Shimokura","year":"2011","unstructured":"Shimokura G, Chai F, Weber D et al (2011) Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic haemodialysis patients. Infect Control Hosp Epidemiol 32:415\u2013424","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1940_CR134","first-page":"CD006420","volume":"8","author":"J Bravo Zuniga","year":"2016","unstructured":"Bravo Zuniga J, Loza Munarriz C, Lopez-Alcalde J (2016) Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database Syst Rev 8:CD006420","journal-title":"Cochrane Database Syst Rev"},{"key":"1940_CR135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-5-13","volume":"5","author":"A Shamshirsaz","year":"2004","unstructured":"Shamshirsaz A, Kamgar M, Bekheirnia M et al (2004) The role of haemodialysis machines dedication in reducing hepatitis C transmission in the dialysis setting in Iran: a multicentre prospective interventional study. BMC Nephrol 5:13","journal-title":"BMC Nephrol"},{"key":"1940_CR136","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","volume":"65","author":"R Fissell","year":"2004","unstructured":"Fissell R, Bragg-Gresham J, Woods J et al (2004) Patterns of hepatitis C prevalence and seroconversion in haemodialysis units from three continents: the DOPPS. Kidney Int 65:2335\u20132342","journal-title":"Kidney Int"},{"key":"1940_CR137","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.ajkd.2006.07.004","volume":"48","author":"A Napoli Di","year":"2006","unstructured":"Di Napoli A, Pezzotti P, Di Lallo D et al (2006) Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 48:629\u2013637","journal-title":"Am J Kidney Dis"},{"key":"1940_CR138","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1523-1755.1998.00823.x","volume":"53","author":"M Jadoul","year":"1998","unstructured":"Jadoul M, Cornu C, van Ypersele de Strihou C (1998) Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 53:1022\u20131025","journal-title":"Kidney Int"},{"key":"1940_CR139","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000188608","volume":"70","author":"P Gilli","year":"1995","unstructured":"Gilli P, Soffritti S, De Paoli Vitali E, Bedani P (1995) Prevention of hepatitis C virus in dialysis units. Nephron 70:301\u2013306","journal-title":"Nephron"},{"key":"1940_CR140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000188234","volume":"68","author":"M Sampietro","year":"1994","unstructured":"Sampietro M, Graziani G, Badalamenti S et al (1994) Detection of hepatitis C virus in dialysate and in blood ultrafiltrate of HCV-positive patients. Nephron 68:140","journal-title":"Nephron"},{"key":"1940_CR141","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/jmv.21190","volume":"80","author":"T Kaiser","year":"2008","unstructured":"Kaiser T, Damerow HC, Tenckhoff S et al (2008) Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. J Med Virol 80:1195\u20131201","journal-title":"J Med Virol"},{"key":"1940_CR142","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0272-6386(00)70310-6","volume":"35","author":"F Fabrizi","year":"2000","unstructured":"Fabrizi F, Martin P, Dixit V et al (2000) Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis 35:122\u2013129","journal-title":"Am J Kidney Dis"},{"key":"1940_CR143","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/ajkd.1998.v31.pm9531181","volume":"31","author":"F Fabrizi","year":"1998","unstructured":"Fabrizi F, Martin P, Dixit V et al (1998) Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis 31:647\u2013654","journal-title":"Am J Kidney Dis"},{"key":"1940_CR144","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/ajkd.2001.21294","volume":"37","author":"S Saab","year":"2001","unstructured":"Saab S, Martin P, Brezina M, Gitnick G, Yee H (2001) Serum alanine aminotransferase in hepatitis C screening of patients on haemodialysis. Am J Kidney Dis 37:308\u2013315","journal-title":"Am J Kidney Dis"},{"key":"1940_CR145","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","volume":"58","author":"A Aghemo","year":"2013","unstructured":"Aghemo A, De Francesco R (2013) New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58:428\u2013438","journal-title":"Hepatology"},{"key":"1940_CR146","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","volume":"146","author":"JM Pawlotsky","year":"2014","unstructured":"Pawlotsky JM (2014) New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146:1176\u20131192","journal-title":"Gastroenterology"},{"key":"1940_CR147","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2017.03.017","volume":"24","author":"R D\u2019Ambrosio","year":"2017","unstructured":"D\u2019Ambrosio R, Degasperi E, Colombo M, Aghemo A (2017) Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol 24:31\u201337","journal-title":"Curr Opin Virol"},{"key":"1940_CR148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40620-017-0446-2","volume":"31","author":"S Aoufi-Rabih","year":"2018","unstructured":"Aoufi-Rabih S, Garc\u00eda-Agudo R, Londo\u00f1o MC, Fraga-Fuentes MD, Barril-Cuadrado (2018) G on behalf on the Spanish Association of the Liver and the Kidney (AEHR). Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease. J Nephrol 31:1\u201313","journal-title":"J Nephrol"},{"key":"1940_CR149","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17474124.2018.1411802","volume":"12","author":"H Hubbard","year":"2018","unstructured":"Hubbard H, Lawitz E (2018) Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C. Expert Rev Gastroenterol Hepatol 12:9\u201317","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1940_CR150","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, Mantry PS et al (2016) Efficacy of Direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150:1590\u20131598","journal-title":"Gastroenterology"},{"key":"1940_CR151","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A et al (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386:1537\u20131545","journal-title":"Lancet"},{"key":"1940_CR152","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D et al (2017) Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377:1448\u20131455","journal-title":"N Engl J Med"},{"key":"1940_CR153","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/liv.13123","volume":"36","author":"S Nicola De","year":"2016","unstructured":"De Nicola S, Aghemo A (2016) The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment. Liver Int 36:791\u2013793","journal-title":"Liver Int"},{"key":"1940_CR154","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.29258","volume":"66","author":"V Saxena","year":"2017","unstructured":"Saxena V, Khungar V, Verna EC et al (2017) Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology 66:1090\u20131101","journal-title":"Hepatology"},{"key":"1940_CR155","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","volume":"36","author":"V Saxena","year":"2016","unstructured":"Saxena V, Koraishy FM, Sise ME et al (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36:807\u2013816","journal-title":"Liver Int"},{"key":"1940_CR156","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/liv.13336","volume":"37","author":"T Li","year":"2017","unstructured":"Li T, Qu Y, Guo Y, Wang Y, Wang L (2017) Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4\u20135 chronic kidney disease: a meta-analysis. Liver Int 37:974\u2013981","journal-title":"Liver Int"},{"key":"1940_CR157","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","volume":"65","author":"RB Fissell","year":"2004","unstructured":"Fissell RB, Bragg-Gresham JL et al (2004) Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 65:2335\u20132342","journal-title":"Kidney Int"},{"key":"1940_CR158","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/TP.0b013e3182848de2","volume":"95","author":"A Ingsathit","year":"2013","unstructured":"Ingsathit A, Kamanamool N, Thakkinstian A, Sumethkul V (2013) Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis. Transplantation 95:943\u2013948","journal-title":"Transplantation"},{"key":"1940_CR159","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.TP.0000164348.16689.03","volume":"80","author":"AM Cueto-Manzano","year":"2005","unstructured":"Cueto-Manzano AM, Morales-Buenrostro LE, Gonz\u00e1lez-Espinoza L et al (2005) Markers of inflammation before and after renal transplantation. Transplantation 80:47\u201351","journal-title":"Transplantation"},{"key":"1940_CR160","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/ndt\/gfv354","volume":"31","author":"E Paoletti","year":"2016","unstructured":"Paoletti E, Bellino D, Signori A et al (2016) Regression of asymptomatic cardiomyopathy and clinical outcome of renal transplant recipients: a long-term prospective cohort study. Nephrol Dial Transpl 31:1168\u20131174","journal-title":"Nephrol Dial Transpl"},{"key":"1940_CR161","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1681\/ASN.2010060668","volume":"22","author":"D Roth","year":"2011","unstructured":"Roth D, Gaynor JJ, Reddy KR et al (2011) Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 22:1152\u20131160","journal-title":"J Am Soc Nephrol"},{"key":"1940_CR162","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","volume":"21","author":"F Fabrizi","year":"2014","unstructured":"Fabrizi F, Martin P, Dixit V, Messa P (2014) Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat 21:314\u2013324","journal-title":"J Viral Hepat"},{"key":"1940_CR163","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/TP.0000000000001953","volume":"102","author":"NY Heo","year":"2018","unstructured":"Heo NY, Mannalithara A, Kim D et al (2018) Long-term patient and graft survival of kidney transplant recipients with hepatitis C virus infection in the United States. Transplantation 102:454\u2013460","journal-title":"Transplantation"},{"key":"1940_CR164","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneph.2015.5","volume":"11","author":"JM Morales","year":"2015","unstructured":"Morales JM, Fabrizi F (2015) Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol 11:172\u2013182","journal-title":"Nat Rev Nephrol"},{"key":"1940_CR165","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/ki.2013.264","volume":"84","author":"F Fabrizi","year":"2013","unstructured":"Fabrizi F, Aghemo A, Messa P (2013) Hepatitis C treatment in patients with kidney disease. Kidney Int 84:874\u2013879","journal-title":"Kidney Int"},{"key":"1940_CR166","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2006.12.016","volume":"46","author":"M Rendina","year":"2007","unstructured":"Rendina M, Schena A, Castellaneta NM et al (2007) The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 46:768\u2013774","journal-title":"J Hepatol"},{"key":"1940_CR167","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","volume":"16","author":"N Kamar","year":"2016","unstructured":"Kamar N, Marion O, Rostaing L et al (2016) Efficacy and safety of sofosbuvir-based antiviral therapy to treat Hepatitis C Virus Infection after kidney transplantation. Am J Transpl 16:1474\u20131479","journal-title":"Am J Transpl"},{"key":"1940_CR168","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","volume":"16","author":"D Sawinski","year":"2016","unstructured":"Sawinski D, Kaur N, Ajeti A et al (2016) Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transpl 16:1588\u20131595","journal-title":"Am J Transpl"},{"issue":"7","key":"1940_CR169","doi-asserted-by":"crossref","first-page":"e0158978","DOI":"10.1371\/journal.pone.0158978","volume":"11","author":"MV Lin","year":"2016","unstructured":"Lin MV, Sise ME, Pavlakis M et al (2016) Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic Hepatitis C Virus Infection. PLoS One 11(7):e0158978","journal-title":"PLoS One"},{"key":"1940_CR170","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/tri.12799","volume":"29","author":"S Beinhardt","year":"2016","unstructured":"Beinhardt S, Al Zoairy R, Ferenci P et al (2016) DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int 29:999\u20131007","journal-title":"Transpl Int"},{"key":"1940_CR171","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/TP.0000000000001618","volume":"101","author":"M Lubetzky","year":"2017","unstructured":"Lubetzky M, Chun S, Joelson A et al (2017) Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents. Transplantation 101:1704\u20131710","journal-title":"Transplantation"},{"key":"1940_CR172","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","volume":"166","author":"M Colombo","year":"2017","unstructured":"Colombo M, Aghemo A, Liu H et al (2017) Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med 166:109\u2013117","journal-title":"Ann Intern Med"},{"issue":"5","key":"1940_CR173","doi-asserted-by":"publisher","first-page":"e12941","DOI":"10.1111\/ctr.12941","volume":"31","author":"AL Morales","year":"2017","unstructured":"Morales AL, Liriano-Ward L et al (2017) Ledipasvir\/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. Clin Transpl 31(5):e12941. https:\/\/doi.org\/10.1111\/ctr.12941","journal-title":"Clin Transpl"},{"issue":"Suppl.1","key":"1940_CR174","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0168-8278(17)30444-0","volume":"66","author":"N Reau","year":"2017","unstructured":"Reau N, Kwo PY, Rhee S et al (2017) MAGELLAN-2: safety and efficacy of glecaprevir\/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1\u20136 infection. J Hepatol 66(Suppl.1):S90\u2013S91","journal-title":"J Hepatol"},{"key":"1940_CR175","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2016.12.020","volume":"66","author":"I Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez I, Mu\u00f1oz-G\u00f3mez R, Pascasio JM et al (2017) Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol 66:718\u2013723","journal-title":"J Hepatol"},{"key":"1940_CR176","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/tri.13118","volume":"31","author":"M Fernandez-Ruiz","year":"2018","unstructured":"Fernandez-Ruiz M, Polanco N, Garcia-Santiago A et al (2018) Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up. Transpl Int 31:887\u2013899","journal-title":"Transpl Int"},{"key":"1940_CR177","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40264-016-0420-2","volume":"39","author":"EJ Smolders","year":"2016","unstructured":"Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM (2016) Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and\/or renal impairment. Drug Saf 39:589\u2013611","journal-title":"Drug Saf"},{"key":"1940_CR178","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/2040622318755651","volume":"9","author":"M Rendina","year":"2018","unstructured":"Rendina M, Castellaneta NM, Losurdo G et al (2018) Primary biliary cirrosis by DAAs-induced HCV clearance: a biological proof of concept. Ther Adv Chronic Dis 9:121\u2013123","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"1940_CR179","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40620-018-0476-4","volume":"31","author":"G Manna La","year":"2018","unstructured":"La Manna G (2018) HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs). J Nephrol 31(2):185\u2013187","journal-title":"J Nephrol"},{"key":"1940_CR180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2012.03.015","volume":"60","author":"LM Kucirka","year":"2012","unstructured":"Kucirka LM, Peters TG, Segev DL (2012) Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis 60:112\u2013120","journal-title":"Am J Kidney Dis"},{"key":"1940_CR181","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/TP.0000000000000479","volume":"99","author":"JR Scalea","year":"2015","unstructured":"Scalea JR, Barth RN, Munivenkatappa R, Philosophe B, Cooper M, Whitlow V, LaMattina JC (2015) Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus + renal allografts. Transplantation 99:1192\u20131196","journal-title":"Transplantation"},{"key":"1940_CR182","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/TP.0000000000002099","volume":"102","author":"M McCauley","year":"2018","unstructured":"McCauley M, Mussell A, Goldberg D et al (2018) Race, risk, and willingness of end-stage renal disease patients without hepatitis C (HCV) to accept an HCV-infected kidney transplant. Transplantation 102:e163\u2013e170","journal-title":"Transplantation"},{"key":"1940_CR183","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.kint.2017.09.002","volume":"92","author":"D Sawinski","year":"2017","unstructured":"Sawinski D, Wyatt CM, Locke JE (2017) Expanding the use of hepatitis C-viremic kidney donors. Kidney Int 92:1031\u20131033","journal-title":"Kidney Int"},{"key":"1940_CR184","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/tri.12954","volume":"30","author":"KR Bhamidimarri","year":"2017","unstructured":"Bhamidimarri KR, Ladino M, Pedraza F et al (2017) Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. Transpl Int 30:865\u2013873","journal-title":"Transpl Int"},{"key":"1940_CR185","first-page":"1105","volume":"377","author":"DS Goldberg","year":"2017","unstructured":"Goldberg DS, Abt PL, Reese PP (2017) THINKER Trial Investigators. Transplanting HCV-infected kidneys into uninfected recipients. N Engl J Med 377:1105","journal-title":"N Engl J Med"},{"key":"1940_CR186","volume-title":"Olysio prescribing information 2017","author":"Janssen Therapeutics","year":"2017","unstructured":"Janssen Therapeutics (2017) Olysio prescribing information 2017. Janssen Therapeutics, Titusville"},{"issue":"3","key":"1940_CR187","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/tid.12696","volume":"19","author":"X Forns","year":"2017","unstructured":"Forns X, Berenguer M, Herzer K et al (2017) Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: the Phase II SATURN study. Transpl Infect Dis 19(3):e12696. https:\/\/doi.org\/10.1111\/tid.12696","journal-title":"Transpl Infect Dis"},{"key":"1940_CR188","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40262-015-0314-y","volume":"55","author":"S Ouwerkerk-Mahadevan","year":"2016","unstructured":"Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A (2016) Drug\u2013drug interactions with the NS3\/4A protease inhibitor simeprevir. Clin Pharmacokinet 55:197\u2013208","journal-title":"Clin Pharmacokinet"},{"key":"1940_CR189","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40262-015-0334-7","volume":"55","author":"E Mogalian","year":"2016","unstructured":"Mogalian E, German P, Kearney BP et al (2016) Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic hcv ns5a inhibitor velpatasvir. Clin Pharmacokinet 55:605\u2013613","journal-title":"Clin Pharmacokinet"},{"key":"1940_CR190","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209394s000lbl.pdf"},{"key":"1940_CR191","unstructured":"https:\/\/www.hep-druginteractions.org\/"},{"key":"1940_CR192","unstructured":"https:\/\/www.hiv-druginteractions.org\/"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-018-1940-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-018-1940-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-018-1940-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:52:17Z","timestamp":1662133937000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-018-1940-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":192,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1007\/s11739-018-1940-9","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"type":"print","value":"1828-0447"},{"type":"electronic","value":"1970-9366"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"28 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Roberto Minutolo has received speaker honoraria\/consultant fees from Abbvie. Alessio Aghemo has received speaker honoraria\/ consultant fees\/travel grants from Abbvie, Gilead, MSD, Janssen, BMS, Alfasigma and research grants from Gilead and Abbvie. Antonio Chirianni has received speaker honoraria\/ consultant fees from Gilead, AbbVie, BMS, MSD. Fabrizio Fabrizi has received consultant fees from Abbvie and MSD. Loreto Gesualdo has no conflict of interest to declare. Edoardo G. Giannini has received speaker honoraria\/consultant fees from AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, MSD, and Novartis. Paolo Maggi has received honoraria\/ consultant fees\/travel grants from Abbvie, Gilead, MSD, Janssen, BMS, ViiV. Vincenzo Montinaro has received speaker honoraria\/travel grants from Abbvie, Janssen, ViiV Healthcare, Alexion, Shire, CSL Behring. Ernesto Paoletti has received consultant fees from Abbvie, Novartis, Vifor Fresenius Pharma. Marcello Persico has received speaker honoraria from Abbvie, BMS, Gilead, MSD. Francesco Perticone has no conflict of interest to declare. Salvatore Petta has received speaker honoraria\/ consultant fees\/travel grants from Abbvie, BMS, Gilead, Intercept, MSD, Polifarma, Tobira. Massimo Puoti has received speaker honoraria from Abbvie Gilead sciences MSD and research grants from Gilead sciences. Giovanni Raimondo has received speaker honoraria\/consultant fees from Abbvie, BMS, Gilead Science, Janssen Cilag, MSD, Bayer, and research grants from Abbvie, BMS, Gilead Science. Maria Rendina has received speaker honoraria\/consultant fees\/travel grants from Abbvie, Gilead, MSD, BMS, Kedrion, Biotest, Griffons, Astellas, Novartis. Anna Linda Zignego has received speaker honoraria\/consulting fees from Abbvie, Gilead, MSD, Janssen, BMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study Informed consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}